Kyra A. Gelderman

Amsterdam, NH, Netherlands

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 30 publications

Post-translationally modified proteins bind and activate complement with implications for cellular uptake and autoantibody formation.

Post-translationally modified proteins bind and activate complement with implications for cellular uptake and autoantibody formation.

Journal: Journal of autoimmunity

Published: January 17, 2025

Autoantibodies and therapeutic antibodies against complement factor H.

Autoantibodies and therapeutic antibodies against complement factor H.

Journal: Immunology letters

Published: December 24, 2024

Autoantibody-positivity before and seroconversion during treatment with anti-PD-1 is associated with immune-related adverse events in patients with melanoma.

Autoantibody-positivity before and seroconversion during treatment with anti-PD-1 is associated with immune-related adverse events in patients with melanoma.

Journal: Journal for immunotherapy of cancer

Published: June 09, 2024

Circulating levels of endogenous complement inhibitors correlate inversely with complement consumption in systemic lupus erythematosus.

Circulating levels of endogenous complement inhibitors correlate inversely with complement consumption in systemic lupus erythematosus.

Journal: European journal of immunology

Published: January 18, 2024

Human anti-C1q autoantibodies bind specifically to solid-phase C1q and enhance phagocytosis but not complement activation.

Human anti-C1q autoantibodies bind specifically to solid-phase C1q and enhance phagocytosis but not complement activation.

Journal: Proceedings of the National Academy of Sciences of the United States of America

Published: December 04, 2023

Targeted complement inhibition using bispecific antibodies that bind local antigens and endogenous complement regulators.

Targeted complement inhibition using bispecific antibodies that bind local antigens and endogenous complement regulators.

Journal: Frontiers in immunology

Published: September 04, 2023

Safety and pharmacodynamic efficacy of eculizumab in aneurysmal subarachnoid hemorrhage (CLASH): A phase 2a randomized clinical trial.

Safety and pharmacodynamic efficacy of eculizumab in aneurysmal subarachnoid hemorrhage (CLASH): A phase 2a randomized clinical trial.

Journal: European stroke journal

Published: August 22, 2023

Does COVID-19 impact the prevalence of myositis specific antibodies in the Netherlands? A comparative nationwide study.

Does COVID-19 impact the prevalence of myositis specific antibodies in the Netherlands? A comparative nationwide study.

Journal: Journal of autoimmunity

Published: April 11, 2023

Complement component 4A protein levels are negatively related to frontal volumes in patients with schizophrenia spectrum disorders.

Complement component 4A protein levels are negatively related to frontal volumes in patients with schizophrenia spectrum disorders.

Journal: Schizophrenia research

Published: December 07, 2022

C1-inhibitor treatment in patients with severe complement-mediated autoimmune hemolytic anemia.

C1-inhibitor treatment in patients with severe complement-mediated autoimmune hemolytic anemia.

Journal: Blood advances

Published: November 23, 2022

Differences in IgG autoantibody Fab glycosylation across autoimmune diseases.

Differences in IgG autoantibody Fab glycosylation across autoimmune diseases.

Journal: The Journal of allergy and clinical immunology

Published: March 10, 2022

An Atypical Case of Idiopathic Nonhistaminergic Angioedema With Anti-C1-INH Antibodies.

An Atypical Case of Idiopathic Nonhistaminergic Angioedema With Anti-C1-INH Antibodies.

Journal: Journal of investigational allergology & clinical immunology

Published: February 15, 2022

Showing 1-12 of 30

Last Updated: 09/26/2026